The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

The federal government is cutting $500 million in research money for development of mRNA vaccines, which were widely used against the COVID-19 virus. Health Secretary Robert F. Kennedy Jr. said in a ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing. “After a ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice within hours.

Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Deborah Fuller, University of Washington (THE CONVERSATION) At a Sept. 4, 2025, ...